EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)Randomisierte kontrollierte StudieOpen Access · CC BY-NC 4.0

CDK4/6-Inhibitors Versus Chemotherapy in Advanced HR+/HER2-Negative Breast Cancer: Results and Correlative Biomarker Analyses of the KENDO Randomized Phase II Trial

Francesco Schettini iD, Michela Palleschi, Francesca Mannozzi, Fara Brasó-Maristany, Lorenzo Cecconetto, Patricia Galván, Marita Mariotti, Alessia Ferrari, Emanuela Scarpi, Anna Miserocchi, Oriana Nanni iD, Esther Sanfeliu und 3 weitere

The Oncologist · 2024

DOI: 10.1093/oncolo/oyad337 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift The Oncologist, 2024. Verfasst von Francesco Schettini und 14 weiteren Autor:innen. Beteiligte Einrichtung: Translational Genomics and Targeted Therapies in Solid Tumors Group, August Pi I Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain. Hauptthemen laut MEDLINE: Breast Neoplasms, Cyclin-Dependent Kinase 4, Cyclin-Dependent Kinase 6, Biomarkers, Tumor. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Agenzia Italiana del Farmaco.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The optimal treatment approach for hormone receptor-positive/HER2-negative metastatic breast cancer (HR+/HER2-negative MBC) with aggressive characteristics remains controversial, with lack of randomized trials comparing cyclin-dependent kinase (CDK)4/6-inhibitors (CDK4/6i) + endocrine therapy (ET) with chemotherapy + ET. Materials and methods We conducted an open-label randomized phase II trial (NCT03227328) to investigate whether chemotherapy + ET is superior to CDK4/6i + ET for HR+/HER2-negative MBC with aggressive features. PAM50 intrinsic subtypes (IS), immunological features, and gene expression were assessed on baseline samples.

Results

Among 49 randomized patients (median follow-up: 35.2 months), median progression-free survival (mPFS) with chemotherapy + ET (11.2 months, 95% confidence interval [CI]: 7.7-15.4) was numerically shorter than mPFS (19.9 months, 95% CI: 9.0-30.6) with CDK4/6i + ET (hazard ratio: 1.41, 95% CI: 0.75-2.64). Basal-like tumors under CDK4/6i + ET exhibited worse PFS (mPFS: 11.4 months, 95% CI: 3.00-not reached [NR]) and overall survival (OS; mOS: 18.8 months, 95% CI: 18.8-NR) compared to other subtypes (mPFS: 20.7 months, 95% CI: 9.00-33.4; mOS: NR, 95% CI: 24.4-NR). In the chemotherapy arm, luminal A tumors showed poorer PFS (mPFS: 5.1 months, 95% CI: 2.7-NR) than other IS (mPFS: 13.2 months, 95% CI: 10.6-28.1). Genes/pathways involved in BC cell survival and proliferation were associated with worse outcomes, as opposite to most immune-related genes/signatures, especially in the CDK4/6i arm. CD24 was the only gene significantly associated with worse PFS in both arms. Tertiary lymphoid structures and higher tumor-infiltrating lymphocytes also showed favorable survival trends in the CDK4/6i arm.

Conclusions

The KENDO trial, although closed prematurely, adds further evidence supporting CDK4/6i + ET use in aggressive HR+/HER2-negative MBC instead of chemotherapy. PAM50 IS, genomic, and immunological features are promising biomarkers to personalize therapeutic choices.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breast NeoplasmsCyclin-Dependent Kinase 4Cyclin-Dependent Kinase 6Biomarkers, TumorErb-b2 Receptor Tyrosine KinasesHumansFemaleMiddle AgedAgedAdultProtein Kinase InhibitorsAntineoplastic Combined Chemotherapy ProtocolsReceptors, EstrogenReceptors, Progesterone

Stichwörter der Autor:innen

CDK4/6-inhibitorsbreast cancerchemotherapyhormone receptorsintrinsic subtypestertiary lymphoid structures

Substanzen

Cyclin-Dependent Kinase 4Cyclin-Dependent Kinase 6Biomarkers, TumorErb-b2 Receptor Tyrosine KinasesProtein Kinase InhibitorsReceptors, EstrogenReceptors, ProgesteroneCDK4 protein, humanCDK6 protein, humanERBB2 protein, human

Autor:innen und Institutionen

  • Translational Genomics and Targeted Therapies in Solid Tumors Group, August Pi I Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain.
  • Medical Oncology Department, Hospital Clinic of Barcelona, Barcelona, Spain.
  • Faculty of Medicine and Health Sciences, University of Barcelona, Barcelona, Spain.
  • Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori," Meldola, Italy.
  • Unit of Biostatistics and Clinical Trials, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori," Meldola, Italy.
  • UO Medicina Oncologia, Ospedale Ramazzini, Azienda USL di Modena, Carpi, Italy.

ORCID-Profile: Francesco Schettini, Oriana Nanni, Aleix Prat

Förderung

  • Agenzia Italiana del Farmaco

Zitieren

APA

Schettini, F., Palleschi, M., Mannozzi, F., Brasó-Maristany, F., Cecconetto, L., Galván, P., Mariotti, M., Ferrari, A., Scarpi, E., Miserocchi, A., Nanni, O., Sanfeliu, E., Prat, A., Rocca, A., & De Giorgi, U. (2024). CDK4/6-Inhibitors Versus Chemotherapy in Advanced HR+/HER2-Negative Breast Cancer: Results and Correlative Biomarker Analyses of the KENDO Randomized Phase II Trial. The Oncologist. https://doi.org/10.1093/oncolo/oyad337

Vancouver

Schettini F, Palleschi M, Mannozzi F, Brasó-Maristany F, Cecconetto L, Galván P, et al. CDK4/6-Inhibitors Versus Chemotherapy in Advanced HR+/HER2-Negative Breast Cancer: Results and Correlative Biomarker Analyses of the KENDO Randomized Phase II Trial. The Oncologist. 2024. doi:10.1093/oncolo/oyad337

BibTeX
@article{Schettini2024,
  author = {Schettini, Francesco and Palleschi, Michela and Mannozzi, Francesca and Brasó-Maristany, Fara and Cecconetto, Lorenzo and Galván, Patricia and Mariotti, Marita and Ferrari, Alessia and Scarpi, Emanuela and Miserocchi, Anna and Nanni, Oriana and Sanfeliu, Esther and Prat, Aleix and Rocca, Andrea and De Giorgi, Ugo},
  title = {CDK4/6-Inhibitors Versus Chemotherapy in Advanced HR+/HER2-Negative Breast Cancer: Results and Correlative Biomarker Analyses of the KENDO Randomized Phase II Trial},
  journal = {The Oncologist},
  year = {2024},
  doi = {10.1093/oncolo/oyad337}
}
Kostenlos starten →